Abivax
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Dec 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for A New Quinoline Derivative for Use in the Treatment and Prevention of Viral Infections (US 10,329,317) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Feb 28, 2027The maintenance fee for Aryl-N-Aryl Derivatives for Treating a RNA Virus Infection (US 11,739,073) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Apr 8, 2027The maintenance fee for Quinoline Derivatives for the Treatment of Inflammatory Diseases (US 10,435,370) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
- 2 fees due May 5 to 28, 2027 · next May 5
- 1 fee due Jul 21, 2027The maintenance fee for Compounds for Use as Therapeutic Agents Affecting P53 Expression And/Or Activity (US 10,538,485) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 23, 2026
- Nov 17 US 12,797,403 Quinoline Derivatives For Use In The Treatment Of Inflammation Diseases
- Oct 20 US 12,767,994 Biomarkers, and Uses in Treatment of Viral Infections, Inflammations, or Cancer
- 1 term has ended since Aug 23, 2026
- Aug 30 US 11,427,566 Compounds Useful for Treating Cancer · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,211,861 | Compositions for and methods of enhancing the immune response to antigens In force · USPTO record | In force | USPTO record | |
| US 8,207,135 | Compositions for and methods of enhancing the immune response to antigens In force · USPTO record | In force | USPTO record | |
| US 10,253,020 | Compounds for Preventing, Inhibiting, or Treating Cancer, Aids And/Or Premature Aging In force · Medium confidence | In force | Medium confidence | |
| US 10,683,284 | Compounds for Preventing, Inhibiting, or Treating Cancer, Aids And/Or Premature Aging In force · Low confidence | In force | Low confidence | |
| US 10,975,063 | Compound, and Production Method Thereof, and Methods of Treatment Using the Compound In force · Low confidence | In force | Low confidence | |
| US 11,014,918 | Compounds and Pharmaceutical Compositions Containing at Least One of the Compounds In force · Low confidence | In force | Low confidence | |
| US 10,538,485 | Compounds for Use as Therapeutic Agents Affecting P53 Expression And/Or Activity In force · High confidence | In force | High confidence | |
| US 10,717,724 | Compounds Useful for Treating Cancer In force · High confidence | In force | High confidence | |
| US 10,870,671 | Method of preparation of alpha galactosyl ceramides compounds In force · USPTO record | In force | USPTO record | |
| US 9,827,237 | Compounds Useful for Treating Diseases Caused by Retroviruses In force · High confidence | In force | High confidence |
Also on record, not counted in the 31: 6 patents in force now held by others · 9 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 2 abandoned · 2 no status recorded
Rows 11 to 14 of 14 are for members. The first 10 are on the company page.
Pro members see all 14 published applications.